References
- International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon: International Agency for Research on Cancer; 2012 [cited 2017 February 01] Available from http://globocan.iarc.fr/Pages/fact_sheets_cancer/.
- International Agency for Research on Cancer.World Cancer Report 2014. Lyon: International Agency for Research on Cancer; 2014.
- Kim Z, Min SY, Yoon CS, Lee HJ, Lee JS, Youn HJ, et al. The basic facts of Korean breast cancer in 2011: Results of a nationwide survey and breast cancer registry database. J Breast Cancer. 2014;17(2):99-106. https://doi.org/10.4048/jbc.2014.17.2.99
- Sinn P, Aulmann S, Wirtz R, Schoff S, Marme F, Varga Z, et al. Multigene assays for classification, prognosis, and prediction in breast cancer: A critical review on the background and clinical utility. Geburtshilfe Frauenheilkd. 2013;73(9):932-940. https://doi.org/10.1055/s-0033-1350831
- Rouzier R, Pronzato P, Chereau E, Carlson J, Hunt B, Valentine WJ. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Breast Cancer Res Treat. 2013;139:621-637. https://doi.org/10.1007/s10549-013-2559-1
- Gyorffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015;17:11. https://doi.org/10.1186/s13058-015-0514-2
- National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Breast cancer [Internet]. Washington: National Comprehensive Cancer Network; 2017 [cited 2017 February 01]. Available from: https://www.nccn. org/professionals/physician_gls/f_guidelines.asp
- Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312. https://doi.org/10.1200/JCO.2007.14.2364
- Gong GY, Kwon MJ, Han JI, Lee HJ, Lee SK, Lee JE, et al. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer. Sci. Rep. 2017. Forthcoming.
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611-622 https://doi.org/10.1373/clinchem.2008.112797
- David AA , Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29(Suppl 1):49-52.
- Clinical and Laboratory Standards Institute. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. CLSI document EP06-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2003.
- Clinical and Laboratory Standards Institute. Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline - second edition. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
- Clinical and Laboratory Standards Institute. Evaluation of precision of quantitative measurement procedures; approved guideline - third edition. CLSI document EP05-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
- Clinical and Laboratory Standards Institute. Interference testing in clinical chemistry; approved guideline - second edition. CLSI document EP07-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
- Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, et al. Treatment of lymph-node-negative, oestrogen-receptorpositive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364(9437):858-868. https://doi.org/10.1016/S0140-6736(04)16981-X
- Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365(9472):1687-1717. https://doi.org/10.1016/S0140-6736(05)66544-0
- Huober J, Thurlimann B. Adjuvant! When the new world meets the old world. Lancet Oncology. 2009;10(11):1028-1029. https://doi.org/10.1016/S1470-2045(09)70323-7
- Food and Drug Administration. Center for Devices and Radiological Health: Guidance for industry and FDA staff - class II special controls guidance document: Gene expression profiling test system for breast cancer prognosis [Internet]. Silver Spring: Food and Drug Administration; 2007 [cited 2017 February 01]. Available from: http://www.fda.gov/Regulatory- Information/Guidances/ucm079163.htm
- Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, et al. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer. 2012;12:456. https://doi.org/10.1186/1471-2407-12-456
- Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem. 2007;53(6):1084-1091. https://doi.org/10.1373/clinchem.2006.076497